Company intelligence / Profile preview
Ab Studio Inc.
- Ownership
- Private
- Development stage
- Phase 1
Overview
Ab Studio has developed novel technology platforms for the discovery and engineering of complex therapeutic antibodies. Their lead programs include trispecific therapeutic antibodies targeting SARS-CoV‑2 and multiple myeloma, both in pre-clinical development. The company has filed several patents, designed/licensed out five bispecifics, and completed over 60 partner/service projects since its founding in 2017[3][5].
- Therapeutic areas
- OncologyNeurologyInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)Bispecific antibodiesTrispecific antibodiesCatalytic antibodies
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Ab Studio Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ab Studio Inc..